Biostax Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTAX research report →
Companywww.biostaxcorp.com
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).
- CEO
- Noreen Griffin
- IPO
- 2010
- Employees
- 4
- HQ
- Winter Park, FL, US
Price Chart
Valuation
- Market Cap
- $7.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 67.11%
- ROIC
- 43.69%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,362,647 · 33.18%
- EPS
- $-0.03 · 70.00%
- Op Income
- $-1,484,950
- FCF YoY
- 62.28%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.73
- Avg Volume
- 1
Get TickerSpark's AI analysis on BTAX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BTAX Coverage
We haven't published any research on BTAX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTAX Report →